» Articles » PMID: 36808595

Exploring the Use of Artificial Intelligence in the Management of Prostate Cancer

Overview
Journal Curr Urol Rep
Publisher Current Science
Specialty Urology
Date 2023 Feb 22
PMID 36808595
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: This review aims to explore the current state of research on the use of artificial intelligence (AI) in the management of prostate cancer. We examine the various applications of AI in prostate cancer, including image analysis, prediction of treatment outcomes, and patient stratification. Additionally, the review will evaluate the current limitations and challenges faced in the implementation of AI in prostate cancer management.

Recent Findings: Recent literature has focused particularly on the use of AI in radiomics, pathomics, the evaluation of surgical skills, and patient outcomes. AI has the potential to revolutionize the future of prostate cancer management by improving diagnostic accuracy, treatment planning, and patient outcomes. Studies have shown improved accuracy and efficiency of AI models in the detection and treatment of prostate cancer, but further research is needed to understand its full potential as well as limitations.

Citing Articles

The Application of Surface Luminance Distribution Measurements to the Evaluation of Neoplastic Lesions of the Prostate Gland.

Tereszkiewicz K, Aebisher D, Wachta H, Kulig L, Osuchowski M, Kaznowska E Cancers (Basel). 2025; 17(4).

PMID: 40002234 PMC: 11853033. DOI: 10.3390/cancers17040639.


Intelligent medicine in focus: the 5 stages of evolution in robot-assisted surgery for prostate cancer in the past 20 years and future implications.

Li J, Tang T, Zong H, Wu E, Zhao J, Wu R Mil Med Res. 2024; 11(1):58.

PMID: 39164787 PMC: 11337898. DOI: 10.1186/s40779-024-00566-z.


Briganti's 2012 nomogram is an independent predictor of prostate cancer progression in EAU intermediate-risk class: results from 527 patients treated with robotic surgery.

Porcaro A, Montanaro F, Baielli A, Artoni F, Brancelli C, Costantino S Asian J Androl. 2024; 26(6):587-591.

PMID: 39075792 PMC: 11614175. DOI: 10.4103/aja202439.


AI-accelerated prostate MRI: a systematic review.

Reinhardt C, Briody H, MacMahon P Br J Radiol. 2024; 97(1159):1234-1242.

PMID: 38718224 PMC: 11186563. DOI: 10.1093/bjr/tqae093.


Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives.

Kielb P, Kowalczyk K, Gurwin A, Nowak L, Krajewski W, Sosnowski R Biomedicines. 2023; 11(6).

PMID: 37371647 PMC: 10295349. DOI: 10.3390/biomedicines11061552.


References
1.
Strom P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney D . Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol. 2020; 21(2):222-232. DOI: 10.1016/S1470-2045(19)30738-7. View

2.
Akatsuka J, Numata Y, Morikawa H, Sekine T, Kayama S, Mikami H . A data-driven ultrasound approach discriminates pathological high grade prostate cancer. Sci Rep. 2022; 12(1):860. PMC: 8764059. DOI: 10.1038/s41598-022-04951-3. View

3.
Lucas M, Jansen I, Dilara Savci-Heijink C, Meijer S, de Boer O, van Leeuwen T . Deep learning for automatic Gleason pattern classification for grade group determination of prostate biopsies. Virchows Arch. 2019; 475(1):77-83. PMC: 6611751. DOI: 10.1007/s00428-019-02577-x. View

4.
Koo K, Lee K, Kim S, Min C, Min G, Lee Y . Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system. World J Urol. 2020; 38(10):2469-2476. DOI: 10.1007/s00345-020-03080-8. View

5.
Trinh L, Mingo S, Vanstrum E, Sanford D, Aastha , Ma R . Survival Analysis Using Surgeon Skill Metrics and Patient Factors to Predict Urinary Continence Recovery After Robot-assisted Radical Prostatectomy. Eur Urol Focus. 2021; 8(2):623-630. PMC: 8505550. DOI: 10.1016/j.euf.2021.04.001. View